MANE Stock — Veradermics Incorporated: Cash, EV, Pipeline

Share price

$106.75

Market cap

$4,460.0M

Cash

$819.9M

Enterprise value

$3,640.1M

Balance sheet

Cash	$819.9M
Debt	$0.0M
Net cash	$819.9M
Enterprise value	$3,640.1M
Basic shares	41.8M shares
Fully diluted shares	47.6M shares
Fully diluted market cap	$5,078.7M
Cash per share	$19.61

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MANE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	VDPHL01	Phase 2	Androgenetic Alopecia; AGA; Male Pattern Baldness	—
Jan 12 - Feb 23	VDPHL01	Phase 3	Androgenetic Alopecia; AGA; Male Pattern Baldness	2H 2026
Jul 13 - Aug 24	VDPHL01 QD	Phase 3	Androgenetic Alopecia (AGA); Androgenetic Alopecia; AGA	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VDPHL01

Phase 2/3 · Active Modality: oral small molecule (extended-release)

Target KATP channel

Indications

pattern hair loss (PHL), males (Phase 2/3)
pattern hair loss (PHL), females (Phase 2/3)

Catalysts

— H1 2027

Status note Lead product candidate; oral ER formulation of minoxidil designed to maximize hair restoration while minimizing cardiac activity. Study '302' Phase 2/3 in males reported positive topline April 27, 2026; confirmatory registration-directed Phase 3 in males completed enrollment through Q2 2026. Study '306' registration-directed Phase 2/3 in females completed enrollment subsequent to Q2 2026. Study '207' Phase 2 open-label PoC (21 males, 28 females) reported positive topline July 15, 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VDPHL01
Lead indication	Androgenetic Alopecia
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06972264	Phase 3	Active, not recruiting	Sponsor	MANE	—	Androgenetic Alopecia; AGA; Male Pattern Baldness	2H 2026
NCT07146022	Phase 3	Active, not recruiting	Sponsor	MANE	—	Androgenetic Alopecia (AGA); Androgenetic Alopecia; AGA	—
NCT06724614	Phase 3	Active, not recruiting	Sponsor	MANE	—	Androgenetic Alopecia; AGA; Male Pattern Baldness	2H 2026
NCT06527365	Phase 2	Active, not recruiting	Sponsor	MANE	—	Androgenetic Alopecia; AGA; Male Pattern Baldness	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Veradermics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	180,000	+155,000	0.95%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

MANE — Veradermics Incorporated